Scroll Top
the only Pupil Selective Miotic

The first and only aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes.
Phase 3
  • Made possible by aceclidine, our novel active ingredient
  • Quickly achieved near vision for on demand needs with a long duration*
  • No impact on distance vision in standard and night conditions*
  • Potential for broadest target patient population
*Based on Phase 2

Presbyopia is the age-related loss of near vision
The lens hardens with age, limiting accommodation and shifting near vision focus
A pinhole pupil only allows light that will focus on the retina as a surrogate for accommodation

Target Pinhole Pupil Size
Research shows reducing the pupil diameter below 2mm dramatically increases depth-of-focus7

“Although differences between studies, DOF increases rapidly as the pupil diameter is reduced below 2mm”

– W. Neil Charman

Research shows reducing pupil diameter improves near vision across a broad range of lighting conditions.8
Effective Pharmacologic Treatment of Presbyopia Requires Adequate Pupil Reduction

Key side effect to avoid is the myopic shift
Triggering the iris for pinhole effect while overstimulating the ciliary muscle causing unwanted refractive change

The Only Pupil Selective Miotic
Research shows aceclidine targets iris sphincter without overstimulating the ciliary muscle6
Achieving a sub 2mm pupil while uniquely avoid the myopic shift 4
Avoiding distance vision impact as limiting factor for pupil size reduction 4

Aceclidine Phase 2 INSIGHT Clinical Trial
Met endpoints for Near Vision improvement
Rapid Onset with Significance for 10 Hours
Met endpoint for no impact to distance vision
  • No change in best corrected normal light distance visual acuity
  • No change in best corrected low luminance distance visual acuity
  • Well tolerated, no drug related serious adverse events
Maintained pupil size in target sweet spot for 10 hours
  • Average pupil size maintained in sweet spot of 1.5mm to 2 mm for up to 10 hours
  • Pupil size correlates to lines of near vision improvement

Broad exclusivity protection
  • 15 granted method of use and formulation patents
  • 7 Patent applications under review
  • 13 Granted method of use and formulation patents
  • 33 Patent applications under review
As well as FDA exclusivity provided by New Chemical Entity status on approval.

Safety history
  • Approved for Glaucoma in Europe in 1970’s6
  • Approved at higher concentration and QID dosing6
  • Rapid anterior chamber penetration
  • Well tolerated with no tachyphylaxis
  • No US DMF submission and therefore a US NCE
Aceclidine Development Progress
LNZ100 and LNZ101 are in Phase 3

Contact Us